{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:25:26Z","timestamp":1777883126252,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V005731\/1"],"award-info":[{"award-number":["MR\/V005731\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the expansion of antiretroviral treatment programmes, the incidence and mortality of HIV-associated cryptococcal meningitis remain high in Africa. Cryptococcal antigen (CrAg) in the blood precedes meningitis. CrAg screening of individuals with advanced HIV disease, combined with pre-emptive fluconazole treatment, reduces the risk of cryptococcal meningitis and associated mortality. However, mortality among individuals with antigenaemia treated with fluconazole is higher than that of CD4-matched individuals with a CrAg-negative test. Autopsy studies have found that cryptococcal disease remains an important cause of death in people with antigenaemia despite pre-emptive antifungal treatment. This suggests a need for more potent treatment for antigenaemia. Flucytosine, combined with fluconazole, is an effective and safe oral treatment for cryptococcal meningitis, and flucytosine has become more widely available as a generic formulation. This trial aims to determine whether combination treatment of fluconazole plus flucytosine is superior to fluconazole monotherapy in reducing all-cause mortality among adults with antigenaemia without evidence of meningitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multi-centre, open-label phase III randomised-controlled trial embedded in routine CrAg screening programmes in South Africa and Tanzania will compare 14 days of fluconazole (1200 mg\/day) plus flucytosine (100 mg\/kg\/day) to fluconazole (1200 mg\/day) alone for the treatment of adults with advanced HIV disease, a blood CrAg-positive test and without evidence of meningitis. Following this 2-week induction therapy, all participants are given fluconazole consolidation and maintenance therapy per local guidelines. The primary endpoint is all-cause mortality at 6 months (superiority analysis). Secondary endpoints include time to all-cause mortality, cryptococcal meningitis-free survival and incidence of symptomatic cryptococcal meningitis, proportion of participants with grade 3 or 4 adverse events, efficacy outcomes by baseline CrAg titre\/CrAg semi-quantitative assay score, and health service and household costs per life year saved. A total of 600 participants will be enrolled, 300 per arm, sufficient to detect a 40% relative reduction in mortality with 91% power.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>An all-oral combination regimen of flucytosine with fluconazole, tested in adults with early cryptococcal disease across a range of baseline CrAg titres, could be an easy-to-administer, safe, and implementable alternative if found to be superior to the current World Health Organization recommended standard of fluconazole monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ISRCTN30579828, registered 04 March 2021, and SANCTR DOH-27-122021-6511, registered 06 December 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09520-x","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:38:53Z","timestamp":1774334333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Kyla","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy S.","family":"Nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahomed-Yunus","family":"Moosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas P.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merika","family":"Tsitsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayoki","family":"Mfinanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sokoine","family":"Kivuyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Kyazze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nowshad","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebrahim","family":"Variava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marise","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vu Quoc","family":"Dat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuy","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Loyse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel M.","family":"Wake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duolao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabbar","family":"Jaffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph N.","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edle F.","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelesh P.","family":"Govender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"9","key":"9520_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1097\/QAD.0b013e32832be0fc","volume":"23","author":"JN Jarvis","year":"2009","unstructured":"Jarvis JN, Boulle A, Loyse A, Bicanic T, Rebe K, Williams A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS. 2009;23(9):1182\u20133.","journal-title":"AIDS"},{"issue":"11","key":"9520_CR2","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","volume":"378","author":"SF Molloy","year":"2018","unstructured":"Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018;378(11):1004\u201317.","journal-title":"N Engl J Med"},{"key":"9520_CR3","doi-asserted-by":"publisher","unstructured":"Wall EC, Everett DB, Mukaka M, Bar-Zeev N, Feasey N, Jahn A, et al. Bacterial meningitis in Malawian adults, adolescents, and children during the era of antiretroviral scale-up and haemophilus influenzae type b vaccination, 2000\u20132012.\u00a0Clin Infect Dis. 2014;58(10):e137-45. https:\/\/doi.org\/10.1093\/cid\/ciu057. Epub 2014 Feb 4. PMID: 24496208;PMCID: PMC4001285.","DOI":"10.1093\/cid\/ciu057"},{"issue":"7","key":"9520_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S1473-3099(16)00128-6","volume":"16","author":"JN Jarvis","year":"2016","unstructured":"Jarvis JN, Harrison TS. Forgotten but not gone: HIV-associated cryptococcal meningitis. Lancet Infect Dis. 2016;16(7):756\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"9520_CR5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873\u201381.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"9520_CR6","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","volume":"22","author":"R Rajasingham","year":"2022","unstructured":"Rajasingham R, Govender NP, Jordan A, Loyse A, Shroufi A, Denning DW, et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect Dis. 2022;22(12):1748\u201355.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"9520_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1086\/597262","volume":"48","author":"JN Jarvis","year":"2009","unstructured":"Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48(7):856\u201362.","journal-title":"Clin Infect Dis"},{"key":"9520_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/1545109712459077","volume":"11","author":"JN Jarvis","year":"2012","unstructured":"Jarvis JN, Govender N, Chiller T, Park BJ, Longley N, Meintjes G, et al. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care. 2012;11:374\u20139.","journal-title":"J Int Assoc Physicians AIDS Care"},{"issue":"3","key":"9520_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1086\/649861","volume":"50","author":"JC Nussbaum","year":"2010","unstructured":"Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010;50(3):338\u201344.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"9520_CR10","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/QAD.0b013e328354b419","volume":"26","author":"AT Jackson","year":"2012","unstructured":"Jackson AT, Nussbaum JC, Phulusa J, Namarika D, Chikasema M, Kanyemba C, et al. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS. 2012;26(11):1363\u201370.","journal-title":"AIDS"},{"issue":"1","key":"9520_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1086\/518607","volume":"45","author":"T Bicanic","year":"2007","unstructured":"Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45(1):76\u201380.","journal-title":"Clin Infect Dis"},{"key":"9520_CR12","doi-asserted-by":"publisher","unstructured":"Gaskell KM, Rothe C, Gnanadurai R, Goodson P, Jassi C, Heyderman RS, et al. A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200mg oral fluconazole in Blantyre, Malawi.\u00a0PLOS ONE. 2014;9(11):e110285. https:\/\/doi.org\/10.1371\/journal.pone.0110285.","DOI":"10.1371\/journal.pone.0110285"},{"issue":"7","key":"9520_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1371\/journal.pone.0069288","volume":"8","author":"JN Jarvis","year":"2013","unstructured":"Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS ONE. 2013;8(7):19.","journal-title":"PLoS ONE"},{"issue":"4","key":"9520_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/655143","volume":"51","author":"DB Meya","year":"2010","unstructured":"Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count \u2264100 cells\/\u03bcL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51(4):448\u201355.","journal-title":"Clin Infect Dis"},{"issue":"9983","key":"9520_CR15","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(15)60164-7","volume":"385","author":"S Mfinanga","year":"2015","unstructured":"Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. The Lancet. 2015;385(9983):2173\u201382.","journal-title":"The Lancet"},{"issue":"5","key":"9520_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/cid\/civ936","volume":"62","author":"N Longley","year":"2016","unstructured":"Longley N, Jarvis JN, Meintjes G, Boulle A, Cross A, Kelly N, et al. Cryptococcal antigen screening in patients initiating ART in South Africa: a prospective cohort study. Clin Infect Dis. 2016;62(5):581\u20137.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"9520_CR17","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/cid\/ciz485","volume":"70","author":"RM Wake","year":"2020","unstructured":"Wake RM, Govender NP, Omar T, Nel C, Mazanderani AH, Karat AS, et al. Cryptococcal-related mortality despite fluconazole preemptive treatment in a cryptococcal antigen screen-and-treat program. Clin Infect Dis. 2020;70(8):1683\u201390.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"9520_CR18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/cid\/cir613","volume":"53","author":"JN Jarvis","year":"2011","unstructured":"Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53(10):1019\u201323.","journal-title":"Clin Infect Dis"},{"key":"9520_CR19","doi-asserted-by":"crossref","unstructured":"Govender NP, Meintjes G, Mangena P, Nel J, Potgieter S, Reddy D, et al. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. South Afr J HIV Med. 2019;20(1).","DOI":"10.4102\/sajhivmed.v20i1.1030"},{"issue":"1","key":"9520_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/cid\/ciae266","volume":"80","author":"DB Meya","year":"2025","unstructured":"Meya DB, Nalintya E, Skipper CP, Kirumira P, Ayebare P, Naluyima R, et al. Adjunctive single-dose liposomal amphotericin to prevent cryptococcal meningitis in people with HIV\u2013associated cryptococcal antigenemia and low plasma cryptococcal antigen titers. Clin Infect Dis. 2025;80(1):129\u201336.","journal-title":"Clin Infect Dis"},{"key":"9520_CR21","doi-asserted-by":"publisher","unstructured":"Rothe C, Sloan DJ, Goodson P, Chikafa J, Mukaka M, Denis B, et al. A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi. PLoS One. 2013;8(6):e67311. https:\/\/doi.org\/10.1371\/journal.pone.0067311.","DOI":"10.1371\/journal.pone.0067311"},{"key":"9520_CR22","doi-asserted-by":"publisher","unstructured":"Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. N Engl J Med. 2022;386(12):1109\u201320. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2111904","DOI":"10.1056\/NEJMoa2111904"},{"key":"9520_CR23","unstructured":"World Health Organisation. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. 2022."},{"issue":"9","key":"9520_CR24","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S1473-3099(22)00234-1","volume":"22","author":"RC Mashau","year":"2022","unstructured":"Mashau RC, Meiring ST, Quan VC, Nel J, Greene GS, Garcia A, et al. Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study. Lancet Infect Dis. 2022;22(9):1365\u201373.","journal-title":"Lancet Infect Dis"},{"key":"9520_CR25","unstructured":"World Health Organisation. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. 2018."},{"key":"9520_CR26","unstructured":"Unitaid. Unitaid invests to cut HIV-related deaths. https:\/\/unitaid.org\/advanced-hiv-disease\/#en. Accessed 1 Dec 2023."},{"issue":"3","key":"9520_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1615822","volume":"377","author":"J Hakim","year":"2017","unstructured":"Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377(3):233\u201345.","journal-title":"N Engl J Med"},{"issue":"5","key":"9520_CR28","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/cid\/cix872","volume":"66","author":"RM Wake","year":"2018","unstructured":"Wake RM, Britz E, Sriruttan C, Rukasha I, Omar T, Spencer DC, et al. High cryptococcal antigen titers in blood are predictive of subclinical cryptococcal meningitis among human immunodeficiency virus-infected patients. Clin Infect Dis. 2018;66(5):686\u201392.","journal-title":"Clin Infect Dis"},{"key":"9520_CR29","doi-asserted-by":"publisher","unstructured":"Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr. 2012;59(5)5):e85-91. https:\/\/doi.org\/10.1097\/QAI.0b013e31824c837e. PMID: 22410867; PMCID: PMC3311156.","DOI":"10.1097\/QAI.0b013e31824c837e."},{"key":"9520_CR30","doi-asserted-by":"publisher","unstructured":"Naicker SD, Mpembe RS, Maphanga TG, Zulu TG, Desanto D, Wadula J, et al. Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade. PLoS Negl Trop Dis. 2020;14(3):e0008137. https:\/\/doi.org\/10.1371\/journal.pntd.0008137.","DOI":"10.1371\/journal.pntd.0008137"},{"issue":"1","key":"9520_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/cid\/ciz163","volume":"70","author":"T Shiri","year":"2020","unstructured":"Shiri T, Loyse A, Mwenge L, Chen T, Lakhi S, Chanda D, et al. Addition of flucytosine to fluconazole for the treatment of cryptococcal meningitis in Africa: a multicountry cost-effectiveness analysis. Clin Infect Dis. 2020;70(1):26\u20139.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"9520_CR32","doi-asserted-by":"publisher","first-page":"e920","DOI":"10.1016\/S2214-109X(25)00010-5","volume":"13","author":"THA Samuels","year":"2025","unstructured":"Samuels THA, Molloy SF, Lawrence DS, Loyse A, Kanyama C, Heyderman RS, et al. Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trials. Lancet Glob Health. 2025;13(5):e920\u201330.","journal-title":"Lancet Glob Health"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09520-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:34:42Z","timestamp":1777599282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09520-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9520"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09520-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for the trial has been obtained from the following research ethics committees:St George\u2019s Research Ethics Committee, reference 2020.0308.University of the Witwatersrand Human Research Ethics Committee,\u00a0reference 210305.University of Kwazulu-Natal Biomedical Research Ethics Committee,\u00a0reference 00002777\u20132021.Walter Sisulu University Health Research Ethics Committee, reference\u00a0067.2021.University of Cape Town Human Research Ethics Committee, reference\u00a0274\/2021.National Institute for Medical Research, Tanzania, reference\u00a0NIMR\/HQ\/R.8c\/Vol.I\/3725.Written informed consent to participate is obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"A model consent form is available on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"345"}}